Background: Most patients (pts) with ES-SCLC receive platinum-based chemotherapy with etoposide, however median survival is <1 y, and new options are needed. Here we assess the safety and clinical activity of the cancer immunotherapy atezo (anti-PDL1) as monotherapy in ES-SCLC. Methods: ES-SCLC pts received atezo IV q3w at 15 mg/kg or 1200 mg as part of a Ph Ia study (NCT01375842). Due to protocol amendments the first 5 pts were PD-L1 selected and the subsequent 12 were not PD-L1 selected.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with L. V.
Contact L. V., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack